About Quibim
Explore Quibim's AI-driven medical imaging solutions for oncology, neurology & metabolic disorders. FDA-cleared tools like QP-Prostate enhance diagnostics & pharmaceutical research through imaging biomarkers.
Overview
- AI-Driven Medical Imaging Pioneer: Quibim develops foundational AI models that transform MRI, CT, and PET scans into actionable insights for precision medicine across oncology, neurology, and immunology.
- Global Clinical Implementation: With FDA/CE/UKCA-cleared solutions deployed in 170+ institutions worldwide including Stanford and Mass General Brigham, Quibim bridges research with clinical practice through quantitative imaging biomarkers.
- Strategic Industry Partnerships: Maintains collaborations with Philips for MR scanner integrations and biopharma leaders like Novartis/Merck KGaA for drug development companion diagnostics.
Use Cases
- Oncology Workflow Optimization: Accelerates prostate cancer diagnosis through AI-assisted MRI interpretation while enabling treatment response prediction via tumor heterogeneity analysis.
- Clinical Trial Enhancement: Provides pharmaceutical partners with imaging biomarkers to stratify patients, monitor therapeutic efficacy in immunotherapy trials (Merck partnership), and reduce drug development timelines.
- Population Health Analytics: Powers Europe's Beating Cancer Plan through management of 10M+ de-identified oncology imaging datasets for predictive public health insights.
Key Features
- QP-Prostate®: AI-powered prostate cancer detection software with 88% segmentation accuracy validated in international studies, featuring automated lesion detection and PSA density calculations.
- Whole-Body Analysis Suite: Combines QP-Brain® (neurological disease quantification), QP-Liver® (diffuse disease diagnosis), and upcoming whole-body digital twin capabilities for comprehensive tissue analysis.
- QP-Insights® Platform: Manages 100M+ medical images through hybrid cloud infrastructure with advanced data harmonization tools that standardize multi-vendor imaging equipment outputs.
Final Recommendation
- Essential for Precision Oncology Programs: Hospitals implementing prostate MRI workflows should prioritize QP-Prostate® integration to improve diagnostic accuracy while reducing radiologist workload.
- Strategic Partner for Drug Developers: Biopharma companies engaged in immunotherapy/neurology trials benefit from Quibim's predictive biomarker panels to enhance patient selection criteria.
- Recommended Imaging Analytics Platform: Healthcare networks managing large-scale imaging repositories require QP-Insights® to unlock longitudinal analysis capabilities across multi-site datasets.
